[go: up one dir, main page]

PE20061119A1 - PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie - Google Patents

PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie

Info

Publication number
PE20061119A1
PE20061119A1 PE2006000065A PE2006000065A PE20061119A1 PE 20061119 A1 PE20061119 A1 PE 20061119A1 PE 2006000065 A PE2006000065 A PE 2006000065A PE 2006000065 A PE2006000065 A PE 2006000065A PE 20061119 A1 PE20061119 A1 PE 20061119A1
Authority
PE
Peru
Prior art keywords
pyrazolo
pyridin
phenyl
fak
kdr
Prior art date
Application number
PE2006000065A
Other languages
English (en)
Inventor
Baptiste Ronan
Michel Tabart
Eric Bacque
Antonio Ugolini
Fabrice Viviani
Catherine Souaille
Frank Halley
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061119(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0500555A external-priority patent/FR2880891B1/fr
Priority claimed from FR0507505A external-priority patent/FR2888579A1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20061119A1 publication Critical patent/PE20061119A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A Y Ar SON CADA UNO ARILO, HETEROARILO, ARILO SUSTITUIDO, HETEROARILO SUSTITUIDO, ENTRE OTROS; L ES ENLACE, CO, NH, CO-NH, SO2NH, ENTRE OTROS; UNO DE X, Y, Z SE ELIGE ENTRE N, NO Y LOS OTROS 2 DE Z, Y, X SON C(R5) Y C(R6); R5 Y R6 SON CADA UNO H, HALOGENO, CN, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-[4-(3-AMINO-1H-PIRAZOLO[3,4-b]PIRIDIN-4-IL)-FENIL]-3-(2-FLUORO-5-TRIFLUOROMETIL-FENIL)-UREA; 1-[5-(3-AMINO-1H-PIRAZOLO[3,4-b]PIRIDIN-4-IL)-PIRIDIN-2-IL]-3-(2-FLUORO-5-TRIFLUOROMETIL-FENIL)-UREA; N-[4-(3-AMINO-1H-PIRAZOLO[3,4-c]PIRIDIN-4-IL)-FENIL]-2,3-DICLORO-BENCENOSULFONAMIDA. SE REFIERE TAMBIEN A INTERMEDIOS UTILIZADOS EN EL PROCESO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS TALES COMO FAK (TIROSINA QUINASA), KDR (RECEPTOR CON DOMINIO DE INSERCION CINASA) Y Tie2 (TIROSINA CINASA ESPECIFICO DE LAS CELULAS ENDOTELIALES) Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2006000065A 2005-01-19 2006-01-16 PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie PE20061119A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500555A FR2880891B1 (fr) 2005-01-19 2005-01-19 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
FR0507505A FR2888579A1 (fr) 2005-07-13 2005-07-13 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
PE20061119A1 true PE20061119A1 (es) 2006-11-27

Family

ID=36593766

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000065A PE20061119A1 (es) 2005-01-19 2006-01-16 PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie

Country Status (24)

Country Link
US (2) US8008322B2 (es)
EP (1) EP1845978B1 (es)
JP (1) JP2008527025A (es)
KR (1) KR20070098923A (es)
AR (1) AR052357A1 (es)
AT (1) ATE477799T1 (es)
AU (1) AU2006207442A1 (es)
BR (1) BRPI0606504A2 (es)
CA (1) CA2595041A1 (es)
CY (1) CY1110926T1 (es)
DE (1) DE602006016233D1 (es)
DK (1) DK1845978T3 (es)
HR (1) HRP20100624T8 (es)
IL (1) IL184524A0 (es)
MX (1) MX2007008790A (es)
PA (1) PA8660301A1 (es)
PE (1) PE20061119A1 (es)
PL (1) PL1845978T3 (es)
PT (1) PT1845978E (es)
RU (1) RU2375360C2 (es)
SI (1) SI1845978T1 (es)
TW (1) TW200639173A (es)
UY (1) UY29341A1 (es)
WO (1) WO2006077319A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1870410A1 (en) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US20090062273A1 (en) * 2006-12-15 2009-03-05 Ingo Hartung 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same.
EP2042500A1 (en) * 2007-09-21 2009-04-01 Bayer Schering Pharma Aktiengesellschaft N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors
EP1932845A1 (en) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
CN101903384A (zh) * 2007-11-02 2010-12-01 沃泰克斯药物股份有限公司 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
CA2711614A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
EP2252293B1 (en) * 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2408772B1 (en) * 2009-03-19 2015-07-01 Medical Research Council Technology Compounds
EP2789614B1 (en) * 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2012015723A1 (en) 2010-07-26 2012-02-02 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
EP2638041B1 (en) 2010-11-12 2015-07-22 Bristol-Myers Squibb Company Substituted azaindazole compounds
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
RU2638116C2 (ru) * 2011-08-12 2017-12-15 Ф. Хоффманн-Ля Рош Аг Пиразоло[3,4-с]пиридины и способы их применения
US9085578B2 (en) 2012-02-20 2015-07-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2013323508B2 (en) * 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EP2940014B1 (en) 2012-12-28 2018-09-26 Crystalgenomics, Inc. 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
AU2019249721B2 (en) 2018-04-05 2024-07-18 Merck Patent Gmbh Heteroaryl compounds as type II IRAK inhibitors and uses hereof
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN118715222A (zh) * 2021-12-22 2024-09-27 阿纳克西斯制药股份有限公司 芳基磺酰胺化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182896B (de) * 1963-04-02 1964-12-03 Merck Ag E Fungizide Mittel
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
PL359416A1 (en) * 2000-07-18 2004-08-23 Yamanouchi Pharmaceutical Co, Ltd. Medicine comprising dicyanopyridine derivative
BR0113176A (pt) * 2000-08-10 2003-06-17 Pharmacia Italia Spa Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
FR2827603B1 (fr) 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
US20050267133A1 (en) * 2002-07-23 2005-12-01 Brown Matthew L Pyrazolopyrimidines as kinase inhibitors
WO2004014368A1 (en) * 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7468376B2 (en) * 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
EP2246333B1 (en) * 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
JP2005325099A (ja) * 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2585934C (en) * 2004-10-29 2013-09-10 Abbott Laboratories Novel pyrazolopyridine urea kinase inhibitors
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
EP1863766B1 (en) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007056582A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (en) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Also Published As

Publication number Publication date
SI1845978T1 (sl) 2010-12-31
EP1845978A1 (fr) 2007-10-24
KR20070098923A (ko) 2007-10-05
DK1845978T3 (da) 2010-12-13
HRP20100624T1 (hr) 2010-12-31
JP2008527025A (ja) 2008-07-24
UY29341A1 (es) 2006-08-31
HRP20100624T8 (hr) 2011-01-31
MX2007008790A (es) 2007-09-11
ATE477799T1 (de) 2010-09-15
US20080039491A1 (en) 2008-02-14
US8008322B2 (en) 2011-08-30
RU2375360C2 (ru) 2009-12-10
IL184524A0 (en) 2007-10-31
WO2006077319A1 (fr) 2006-07-27
BRPI0606504A2 (pt) 2009-06-30
AU2006207442A1 (en) 2006-07-27
RU2007131274A (ru) 2009-02-27
PL1845978T3 (pl) 2011-02-28
CA2595041A1 (fr) 2006-07-27
EP1845978B1 (fr) 2010-08-18
US20110190337A1 (en) 2011-08-04
AR052357A1 (es) 2007-03-14
PT1845978E (pt) 2010-11-29
PA8660301A1 (es) 2006-09-08
DE602006016233D1 (de) 2010-09-30
CY1110926T1 (el) 2015-06-10
TW200639173A (en) 2006-11-16

Similar Documents

Publication Publication Date Title
PE20061119A1 (es) PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
US11065231B2 (en) Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
CA2572833C (en) Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US7834025B2 (en) Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
TNSN05252A1 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them
PE20091955A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20080205A1 (es) DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
EP3484887A1 (en) Wee-1 inhibiting pyrazolopyrimidinone compounds
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
BR112013009036A2 (pt) antagonstas do receptor cxcr4
WO2015121812A1 (en) Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
PE20091307A1 (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica
JP2025183201A (ja) アデノシンａ２ａ受容体のアンタゴニスト
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20120632A1 (es) Inhibidores de bace
RU2007133655A (ru) Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
BRPI0713576A2 (pt) composto, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar condição, distúrbio e doença, para aumentar a formação óssea, para aumentar a formação óssea de estrutura esponjosa e/ou nova formação óssea, para aumentar a densidade mineral óssea, para reduzir a incidência de fratura e para melhorar a cicatrização de fratura, e, processo para preparar um composto
RU2005127335A (ru) Новые производные цикломочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
AU2007206941A1 (en) Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase

Legal Events

Date Code Title Description
FC Refusal